Related Experiment Video

Updated: Jan 30, 2026

Implantation of Combined Telemetric ECG and Blood Pressure Transmitters to Determine Spontaneous Baroreflex Sensitivity in Conscious Mice
09:56

Implantation of Combined Telemetric ECG and Blood Pressure Transmitters to Determine Spontaneous Baroreflex Sensitivity in Conscious Mice

Published on: February 14, 2021

5.9K

Baroreflex stimulation in the treatment of hypertension

John D Filippone1, John D Bisognano

  • 1Cardiology Division, Department of Medicine, University of Rochester Medical Center, Rochester, New York 14642-8679, USA.

Current Opinion in Nephrology and Hypertension
|August 19, 2007
PubMed

Insights

Electrical baroreflex stimulation offers a new treatment for resistant hypertension. This novel therapy safely lowers blood pressure by activating the baroreflex, potentially reducing cardiovascular risks.

Area of Science:

  • Cardiology
  • Nephrology
  • Neurology

Background:

  • Resistant hypertension poses significant cardiovascular risks despite medical therapy.
  • Baroreceptors are crucial for long-term blood pressure regulation.
  • The baroreflex attenuates hypertension by inhibiting renal sympathetic tone.

Purpose of the Study:

  • To evaluate electrical stimulation of the carotid sinus as a novel treatment for hypertension.
  • To assess the safety and efficacy of baroreflex activation in managing blood pressure.

Main Methods:

  • Review of evidence on baroreceptor function and baroreflex mechanisms.
  • Analysis of animal and human studies on electrical carotid sinus stimulation.
  • Assessment of blood pressure reduction and sympathetic tone modulation.

Main Results:

  • Electrical carotid sinus stimulation demonstrated safe and effective blood pressure lowering in studies.
  • Evidence supports a significant role for baroreceptors in chronic hypertension management.
  • The baroreflex appears to mitigate hypertension primarily through renal sympathetic inhibition.

Conclusions:

  • Electrical baroreflex stimulation is a safe and effective adjunct therapy for resistant hypertension.
  • Implantable carotid sinus stimulators show promise for treating hypertension.
  • This approach may offer a valuable alternative or addition to conventional medical treatments.
Abstract

More Related Videos

Vagus Nerve Stimulation As an Adjunctive Neurostimulation Tool in Treatment-resistant Depression04:29

Vagus Nerve Stimulation As an Adjunctive Neurostimulation Tool in Treatment-resistant Depression

Published on: January 7, 2019

29.6K
Laser-Induced Chronic Ocular Hypertension Model on SD Rats06:34

Laser-Induced Chronic Ocular Hypertension Model on SD Rats

Published on: December 3, 2007

11.8K

Related Concept Videos

Hypertension I: Introduction01:28

Hypertension I: Introduction

Hypertension is a widespread, long-term medical condition where blood pressure in the arteries remains elevated. It is characterized by systolic blood pressure readings of 130 mm Hg or above or diastolic blood pressure (DBP) readings of 80 mm Hg or higher. Unmanaged hypertension poses significant health risks, making the distinction between primary (or essential) hypertension and secondary hypertension crucial, as their management and implications vary.Primary HypertensionPrimary hypertension,...
862
Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors01:28

Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors

Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
600
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists01:18

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
464
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
507
Treatment for Pulmonary Arterial Hypertension: Oxygen Therapy for Respiratory Failure01:16

Treatment for Pulmonary Arterial Hypertension: Oxygen Therapy for Respiratory Failure

Oxygen therapy has emerged as a significant tool in enhancing the quality of life for patients suffering from pulmonary arterial hypertension (PAH). While this therapy has principally been studied on patients with significant hypoxemia, this therapeutic approach helps prevent potential organ damage and can be administered in the comfort of one's home.
Oxygen therapy is vital in increasing and maintaining blood oxygen levels in PAH patients. As a result, it aids in reducing fatigue,...
616
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers01:26

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
529